SHORT MINI-FUTURE - GENMAB | Delayed Deutsche Boerse AG 10:52:52 2024-05-24 EDT | ||
| 33.63 EUR | +4.86% |
|
| Current month | -3.32% | ||
| 1 month | -0.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 33.63 | +4.86% |
| 24-05-23 | 32.07 | +1.55% |
| 24-05-22 | 31.58 | -2.11% |
| 24-05-21 | 32.26 | +1.61% |
| 24-05-17 | 31.75 | -0.22% |
Delayed Quote Deutsche Boerse AG
Last update May 24, 2024 at 10:52 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VU0H1V |
| ISIN | DE000VU0H1V5 |
| Date issued | 2022-12-05 |
| Strike | 4,423 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 16.19 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 34.76 € |
|---|---|
| Lowest since issue | 15.19 € |
| Spread | 0.48 € |
| Spread % | 1.43% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
2,025
DKK
Average target price
2,466
DKK
Spread / Average Target
+21.77%
- Stock Market
- Certificates
- Certificat
